Search
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalTumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
Categories: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, Cytochrome P-450 SubstratesBerberine
go.drugbank.com/drugs/DB04115ApprovedInvestigationalWithdrawnAn alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. … It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalIt was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsMinaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesHuman C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]
Tetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.
Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaBithionol
go.drugbank.com/drugs/DB04813ApprovedWithdrawnApprovals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)). … Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders.
Categories: Anti-Acne Preparations for Topical UseNystatin
go.drugbank.com/drugs/DB00646ApprovedInvestigationalVet approvedNystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate for
Categories: Antifungals for Topical Use, Antibacterials for Systemic UseDimethyl sulfoxide
go.drugbank.com/drugs/DB01093ApprovedInvestigationalVet approvedBecause of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation.
Categories: Topical Products for Joint and Muscular Pain, Cytochrome P-450 CYP2C19 InhibitorsNelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigationalNelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL … [A2331,AA2334,A2335] Results from 2 phase 2 studies on adult and pediatric T-ALL/T-LBL indicated that nelarabine can yield a 13% complete response (CR) rate in pediatric patients and 18% in adult patients